Severe cytokine release syndrome in a patient receiving PD-1-directed therapy

Pediatric Blood and Cancer

Volumn 64, Issue 12, 2017, Pages

  Rotz, Seth J ^a   Leino, Daniel ^a   Szabo, Sara ^a   Mangino, Jennifer L ^a   Turpin, Brian K ^a   Pressey, Joseph G ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

cytokine release syndrome; IL 6; nivolumab; PD 1 inhibitor; tocilizumab

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; DEXAMETHASONE; FIBRINOGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROCORTISONE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; LACTIC ACID; NIVOLUMAB; PAZOPANIB; PROGRAMMED DEATH 1 RECEPTOR; SODIUM CHLORIDE; SUNITINIB; TOCILIZUMAB; TUMOR NECROSIS FACTOR; CYTOKINE; PROGRAMMED DEATH 1 LIGAND 1;

ACUTE KIDNEY FAILURE; ADULT; ALVEOLAR SOFT PART SARCOMA; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CELL COUNT; BLOOD CULTURE; BODY TEMPERATURE; BONE METASTASIS; BRAIN DISEASE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CASE REPORT; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; COUGHING; CYTOKINE RELEASE SYNDROME; DIPLOPIA; DISEASE MARKER; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FIBRINOGEN BLOOD LEVEL; FLUID RESUSCITATION; FOLLOW UP; GAMMA KNIFE RADIOSURGERY; HEADACHE; HEART RATE; HISTOLOGY; HOSPITAL DISCHARGE; HUMAN; HYPOTENSION; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LEG; LIVER FUNCTION; LIVER INJURY; LUNG METASTASIS; MACULOPAPULAR RASH; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MYALGIA; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS CANCER; PRIORITY JOURNAL; SHOULDER; TACHYCARDIA; THINKING; THORAX RADIOGRAPHY; THORAX WALL CANCER; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR BIOPSY; URINALYSIS; ANTAGONISTS AND INHIBITORS; COMPLICATION; LUNG ALVEOLUS; LUNG TUMOR; METABOLISM; SARCOMA; SYNDROME;

ADULT; B7-H1 ANTIGEN; CYTOKINES; FEMALE; HUMANS; LUNG NEOPLASMS; PULMONARY ALVEOLI; SARCOMA; SYNDROME;

EID: 85019702272     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.26642     Document Type: Article

References (18)

1. Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121:5154–5157.
2. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–95.
3. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–133.
4. Weber JS, Yang JC, Atkins MB, et al. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015;33:2092–2099.
5. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra25.
6. Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6:664–679.
7. Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94:2217–2224.
8. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5:177ra38.
9. Xu X-J, Tang Y-M. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. Cancer Lett. 2014;343:172–178.
10. Mole R. Whole body irradiation—radiobiology or medicine? Br J Radiol. 1953;26:234–241.
11. Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58:862–870.
12. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925–931.
13. Golden EB, Pellicciotta I, Demaria S, et al. The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol. 2012;2:88.
14. Shiao SL, Coussens LM. The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia. 2010;15:411–421.
15. Porta C, Paglino C, Imarisio I, et al. Immunological effects of multikinase inhibitors for kidney cancer: A clue for integration with cellular therapies. J Cancer. 2011;2:333–338.
16. Ko JS, Rayman P, Ireland J, et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 2010;70:3526–3536.
17. Massari F, Santoni M, Ciccarese C, et al. PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises. Cancer Treat Rev. 2015;41:114–121.
18. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res. 2009;15:7412–7420.